financetom
Business
financetom
/
Business
/
JPMorgan promotes Porretti, Novak to co-head shareholder engagement as more activist campaigns loom
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan promotes Porretti, Novak to co-head shareholder engagement as more activist campaigns loom
Jul 30, 2024 8:47 AM

NEW YORK (Reuters) - JPMorgan Chase ( JPM ) on Tuesday tapped veteran bankers Alfredo Porretti and Darren Novak to co-head its global shareholder engagement and M&A capital markets group at a time corporations are increasingly looking for help to defend against activist investors pushing for changes.

Porretti and Novak, who joined JPMorgan ( JPM ) in 2021 to lead the bank's shareholder activism defense efforts in North America and Europe, Middle East and Africa will oversee the group alongside David Freedman. The bank announced the moves in a memo seen by Reuters.

In 2020, JPMorgan ( JPM ) restructured its efforts to assist clients when activists knock on the door and appointed Freedman, who joined the bank when it acquired Bear Stearns during the financial crisis, to lead the group globally.

Before taking over the activism defense mandate, Freedman had led the bank's capital markets unit.

In the last months, JPMorgan ( JPM ) defended Walt Disney ( DIS ), defeating Nelson Peltz's Trian Fund Management when the hedge fund pushed for a second time for board seats earlier this year.

The bank also worked with asset management firm BlackRock ( BLK ) when Boaz Weinstein's Saba Capital Management pushed for changes at some of its closed-end funds.

It also worked with Bath & Body Works ( BBWI ) as it faced off against Daniel Loeb's Third Point and helped toymaker Hasbro ( HAS ) defeat a board challenge from newcomer Alta Fox.

Over the last years, the group has surged in league table rankings that count banks' mandates. In 2023 JPMorgan ( JPM ) ranked in the No.2 spot behind Goldman Sachs ( GS ), up from the No. 8 spot where it ranked in 2020, according to LSEG data.

The second half of the year is expected to be busy, lawyers and investment managers said, noting that activists are launching campaigns where they often hope to push for some sort of spin off or sale of the entire company or to replace top executives.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Smith Douglas Q3 home closing revenue falls 6%, net orders rise 15%
Smith Douglas Q3 home closing revenue falls 6%, net orders rise 15%
Nov 5, 2025
Overview * Smith Douglas Q3 home closing revenue falls 6% yr/yr, with gross margin declining to 21% * Net new home orders rise 15% in Q3, showing growth in demand * Active community count up 32% to 98, reflecting expansion efforts Outlook * Company did not provide specific financial guidance for future quarters Result Drivers * EXPANSION EFFORTS - Co...
FIS beats Q3 revenue estimates, raises full-year 2025 outlook 
FIS beats Q3 revenue estimates, raises full-year 2025 outlook 
Nov 5, 2025
Overview * FIS Q3 revenue grows 6% to $2.7 bln, beating analyst expectations * Adjusted EPS for Q3 rises 8% to $1.51, surpassing consensus * Company raises full-year 2025 outlook for revenue, adjusted EBITDA, and free cash flow Outlook * FIS raises full-year 2025 revenue growth outlook to 5.4%-5.7% * Company expects full-year 2025 adjusted EPS growth of 10%-11% *...
Chevron nears a final green light on expansion of Israeli Leviathan gas field
Chevron nears a final green light on expansion of Israeli Leviathan gas field
Nov 5, 2025
LONDON, Nov 5 (Reuters) - Chevron ( CVX ) is nearing a final investment decision for a potential capacity expansion of the Leviathan gas field off Israel's Mediterranean coast, it said on Wednesday. In August, partners in the Leviathan natural gas field signed the largest export agreement in Israel's history, worth up to $35 billion, to supply gas to Egypt,...
Larimar Therapeutics Q3 net loss widens
Larimar Therapeutics Q3 net loss widens
Nov 5, 2025
Overview * Larimar reports Q3 net loss of $47.7 mln, driven by increased R&D expenses * Company modifies nomlabofusp dosing to reduce anaphylaxis risk * BLA submission for nomlabofusp targeted for Q2 2026 Outlook * Larimar targets BLA submission for nomlabofusp in Q2 2026 * Company plans U.S. launch of nomlabofusp in early 2027 * Larimar implementing modified dosing regimen...
Copyright 2023-2026 - www.financetom.com All Rights Reserved